PSMB4

PSMB4 is the β7 subunit of the 20S proteasome core and functions both as an essential structural component of the proteasome and as a node coupling ubiquitin-dependent protein turnover to cell survival, inflammatory signaling, and antiviral defense (PMID:15660529, PMID:32651614). As a core subunit it is the docking site for substrate-delivery and regulatory factors: the E3 ubiquitin ligase SNEV/Prp19 binds PSMB4 directly and escorts ubiquitinated substrates to the proteasome, an interaction conserved between yeast and mammals (PMID:15660529), while the presynaptic scaffold bassoon binds PSMB4 through three interfaces and sterically interferes with 20S core assembly to attenuate all proteasomal endopeptidase activities, causing accumulation of proteasomal substrates (PMID:32651614). PSMB4 was the first proteasomal subunit shown to have oncogenic properties, being required for cancer cell survival and tumor growth across many cell lines (PMID:24755469). In tumor contexts it is transcriptionally driven by FoxM1 (PMID:31699366) and promotes proliferation, invasion, and angiogenesis through an NF-κB axis—activating NF-κB and upregulating miR-21 (PMID:25656574), degrading IκBα to sustain NF-κB activity (PMID:33954843), and elevating pFAK/MMP9, MLC, and VEGF-B/VEGFR2 to support migration and neovascularization (PMID:29414809, PMID:38791597). PSMB4 also acts as an antiviral restriction factor: it binds and destabilizes influenza A virus NS1 (PMID:36298834) and PRRSV Nsp1α, mediating K63-linked ubiquitination of Nsp1α at K169 to route it for autolysosomal degradation via LC3 while activating NF-κB/type I interferon signaling, with binding mapped to the PSMB4 C-terminus (aa 250–264) and critical residues S146/M148 (PMID:36943051, PMID:40192860).

1. 2005 High

   Established that PSMB4 serves as a physical docking point linking ubiquitin-tagged substrate delivery to the proteasome core, answering how an E3 ligase couples to the 20S particle.

   Evidence Reciprocal Co-IP, yeast two-hybrid, and immunofluorescence with proteasome inhibition in mammalian and yeast systems

   PMID:15660529

   Open questions at the time

   • No structural definition of the SNEV-PSMB4 interface
   • Whether this interaction modulates proteasome catalytic activity not addressed
2. 2014 High

   Demonstrated that a core proteasomal subunit can itself be oncogenic, reframing PSMB4 from a passive structural part to a survival-promoting cancer dependency.

   Evidence RNAi loss-of-function across 32 cancer cell lines with in vivo xenograft validation

   PMID:24755469

   Open questions at the time

   • Mechanism distinguishing PSMB4 dependency from general proteasome requirement unclear
   • No downstream effectors identified in this study
3. 2015 Medium

   Placed PSMB4 upstream of an NF-κB–miR-21 proliferative axis and linked it to neuronal apoptosis, beginning to define the signaling consequences of its expression.

   Evidence Gain/loss-of-function with miR-21 rescue in myeloma cells; siRNA in primary neurons and LPS neuroinflammation model

   PMID:25656574 PMID:26282113

   Open questions at the time

   • No biochemical mechanism for how PSMB4 activates NF-κB shown here
   • Single-lab observations
4. 2016 Low

   Extended PSMB4's regulatory reach to the RIP3/MLKL necroptosis pathway following spinal cord injury.

   Evidence Expression analysis, co-localization, and gain/loss-of-function in a TNF-α necroptosis cell model

   PMID:27514644

   Open questions at the time

   • Pathway placement based on co-localization and expression without direct biochemical interaction
   • Not independently confirmed
5. 2018 Medium

   Identified pFAK and MMP9 as downstream effectors through which PSMB4 drives glioblastoma invasion, connecting it to an invasion/migration program.

   Evidence siRNA knockdown with proliferation, invasion, apoptosis assays and orthotopic xenograft

   PMID:29414809

   Open questions at the time

   • Direct biochemical link between PSMB4 and FAK/MMP9 regulation not established
   • Single lab
6. 2019 Medium

   Defined the upstream transcriptional control of PSMB4 by showing FoxM1 directly binds its promoter, establishing a FoxM1–PSMB4 axis driving proliferation.

   Evidence ChIP/promoter binding, siRNA, overexpression, rescue, and TCGA correlation in cervical cancer

   PMID:31699366

   Open questions at the time

   • Whether FoxM1 regulation generalizes across cancer types not tested
   • Single lab
7. 2020 High

   Revealed that PSMB4 is a regulatory target whose engagement controls proteasome activity, showing bassoon binds PSMB4 via three interfaces to sterically block 20S assembly and locally tune proteasomal degradation at synapses.

   Evidence Co-IP, deletion mapping, proteasome activity assays, bassoon KO mouse synaptic fractions, and rescue in primary neurons

   PMID:32651614

   Open questions at the time

   • Atomic structure of the bassoon-PSMB4 interface not resolved
   • Whether other scaffolds use a similar mechanism unknown
8. 2021 Medium

   Provided a direct molecular mechanism for PSMB4-driven NF-κB activation by showing it binds IκBα and promotes its proteasomal degradation, protecting cardiomyocytes from apoptosis.

   Evidence Co-IP, gain/loss-of-function in cardiomyocyte hypoxia/reoxygenation model with NF-κB and apoptosis readouts

   PMID:33954843

   Open questions at the time

   • Whether IκBα is a direct catalytic substrate of the PSMB4-containing proteasome or recruited indirectly not resolved
   • Single lab
9. 2022 Medium

   Established PSMB4 as an antiviral restriction factor by showing it binds influenza A NS1 and promotes its proteasome-dependent degradation to restore interferon responses.

   Evidence Yeast two-hybrid with domain mapping, Co-IP, confocal microscopy, MG132 protein-level assays, and IAV replication assays

   PMID:36298834

   Open questions at the time

   • Ubiquitin-linkage type and degradation route for NS1 not defined
   • Single lab
10. 2023 High

    Defined a complete antiviral mechanism in which PSMB4 mediates K63-linked ubiquitination of PRRSV Nsp1α at K169 for LC3-dependent autolysosomal degradation while activating NF-κB/IFN, with the interaction mapped to the PSMB4 C-terminus.

    Evidence Yeast two-hybrid, Co-IP, GST pulldown, confocal, K63 ubiquitination assays, autolysosome and NF-κB assays with PRRSV replication readouts

    PMID:36943051

    Open questions at the time

    • How a 20S core subunit catalyzes K63-linked ubiquitination mechanistically unexplained
    • Whether PSMB4 acts as or recruits the E3 ligase unclear
11. 2025 Medium

    Mapped the specific PSMB4 residues S146 and M148 required for binding and degrading PRRSV Nsp1α, refining the structural basis of antiviral recognition.

    Evidence Yeast two-hybrid, Co-IP, confocal, structure prediction, and truncated/point mutant assays with viral protein readouts

    PMID:40192860

    Open questions at the time

    • Predicted rather than experimental structure
    • Single lab

• How PSMB4's structural role in the 20S core mechanistically gives rise to its substrate-selective, ubiquitin-linkage-specific, and signaling-regulatory activities remains unresolved.
• No structural model of PSMB4 within an active proteasome bound to its regulatory partners
• Unclear whether oncogenic and antiviral functions reflect proteasome-intrinsic activity or moonlighting interactions
• Mechanism by which PSMB4 directs K63 ubiquitination toward the autolysosomal pathway undefined